KYNB - Kyntra Bio, Inc. News

Sectors

KYNB

Kyntra Bio, Inc.

7.12

1 x 7.13

2 x 7.20

bid

ask

0.18

2.46%

11:01 AM

timesize

Ytd	-25.05%
1y	-25.05%

7.13

day range

7.30

6.32

52 week range

12.60

Open	7.30	Prev Close	7.30	Low	7.13	High	7.30	Mkt Cap	29.55M
Vol	3.26K	Avg Vol	18.47K	EPS	-12.34	P/E	-0.59	Forward P/E	N/A
Beta	0.96	Short Ratio	N/A	Inst. Own	N/A	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-10	50-d Avg	7.05	200-d Avg	8.14	1yr Est	0.00

KYNB News

defenseworld.net

Head-To-Head Comparison: Kyntra Bio (NASDAQ:KYNB) and Pharmaxis (OTCMKTS:PXSLY)

Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both

benzinga.com

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations Fo

Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, S

benzinga.com

Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform ra

benzinga.com

Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardl

The presentation at EHA also provides additional details on the subgroup of patients (n=37) who met

globenewswire.com

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ri

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additiona

benzinga.com

Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) w

seekingalpha.com

Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

zacks.com

Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estim

benzinga.com

Kyntra Bio Q1 EPS $(3.76) Down From $1.15 YoY, Sales $3.738M Up From $2.739M YoY

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.76) per share. This is a 426.96 percent de

globenewswire.com

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial r

benzinga.com

Earnings Scheduled For May 11, 2026

globenewswire.com

Kyntra Bio to Report First Quarter 2026 Financial Results

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first

zacks.com

Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

Kyntra Bio (KYNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the

globenewswire.com

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the

seekingalpha.com

Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

benzinga.com

Kyntra Bio Q4 EPS $(3.61) Beats $(3.71) Estimate, Sales $1.300M Miss $1.425M Estimate

Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(3.61) per share which beat the analyst conse

globenewswire.com

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targe

benzinga.com

Earnings Scheduled For March 16, 2026

zacks.com

Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings b

globenewswire.com

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasd

benzinga.com

What's Going On With Kyntra Bio Stock Tuesday?

Kyntra Bio Inc. (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday's premarket session

globenewswire.com

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Co

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasda

globenewswire.com

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it i

seekingalpha.com

FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Tha

zacks.com

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimat

globenewswire.com

FibroGen to Report Third Quarter 2025 Financial Results

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third q

globenewswire.com

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Met

SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the

globenewswire.com

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that